Mental Health Weekly
November 5, 2022
Valerie A. Canady
Acknowledging the barrage of research, media attention and capital investment focused on psychedelic compounds and the race to reach U.S. Food and Drug Administration (FDA) approval for such currently illegal drugs as psilocybin, nearly two dozen experts have weighed in on a new report that, among other things, calls attention to the critical role they said therapists play in the...
The International Journal of Neuropsychopharmacology
November 4, 2022
Aaron Klaiber, Friederike Holze, Ioanna Istampoulouoglou et al.
100 citations
Abstract Background Lysergic acid diethylamide (LSD) is currently being investigated in psychedelic-assisted therapy. LSD has a long duration of acute action of 8–11 hours. It produces its acute psychedelic effects via stimulation of the serotonin 5-hydroxytryptamine-2A (HT2A) receptor. Administration of the 5-HT2A antagonist ketanserin before LSD almost fully blocks the acute subjective...
Frontiers in Psychiatry
November 3, 2022
Devon Christie, Berra Yazar-Klosinski, Ekaterina Nosova et al.
8 citations
IntroductionIncreasing evidence demonstrates 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) may be a safe and effective treatment for post-traumatic stress disorder (PTSD). There is growing interest in MDMA-AT to address a range of other health challenges. Chronic pain and PTSD are frequently comorbid, reciprocally interdependent conditions, though the possible role of...
The Brown University Psychopharmacology Update
November 3, 2022
Two sessions of psilocybin‐assisted psychotherapy resulted in reduced heavy‐drinking days and other alcohol‐related problems relative to placebo plus psychotherapy in a randomized trial involving patients with alcohol use disorder (AUD). There were no serious adverse events associated with psilocybin administration, and no signs of psychotic disturbances. Study results were published online...
Frontiers in Psychiatry
November 3, 2022
Lauren Okano, Bri Deyo, Alida Brandenburg et al.
24 citations
Research of psychedelic assisted therapies is at an all-time high, though few studies highlight extra-pharmacological factors that may affect treatment efficacy. One critical set of attributes includes the therapeutic setting itself, which describe the physical and socio-cultural environments in which the drug-assisted session occurs. Despite enduring consensus of the influence of setting,...
Neuroscience & Biobehavioral Reviews
November 2022
R Guglielmo, G Hasler
The monoamine hypothesis has dominated research on the pathophysiology of mood disorders as well as the development of therapeutic drugs by over half a century. Nowadays a change of perspective is taking place. The glutamate system is increasingly implicated in the pathophysiology of mood disorders. The evidence spans from animal, post-mortem, imaging, pharmacological and genome-wide...
Pharmacology & Therapeutics
November 1, 2022
Sanket B Raut, Padmaja A Marathe, Liza Van Eijk et al.
62 citations
Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options. Current treatment guidelines recommend psychotherapy as first line management with only two drugs, sertraline and paroxetine, approved by U.S. Food and Drug Administration (FDA) for treatment of PTSD. These drugs have...
European Neuropsychopharmacology
November 1, 2022
Marco Solmi, Chaomei Chen, Charles Dauré et al.
55 citations
A scientometric analysis was realized to outline clinical research on psychedelics over the last century. Web of Science Core Collection was searched up to March 18, 2022, for publications on psychedelics. Network analyses and bibliometrics were combined, to identify research themes and trends with Bibliometrix and CiteSpace. The primary aim was to measure research trends evolution over time,...
Online Journal of Complementary & Alternative Medicine
October 28, 2022
Winston de la Haye
2 citations
Proclaimed as the "new frontier" in psychiatry, the use of Psychedelics, including Psilocybin as a treatment for mental health and wellbeing has gained momentum over the last few years [1,2].The scientific progress and clinical promise of this movement owes much of its success to the history of indigenous healing practices.Though "discovered" in 1956 by Roger Heim [3], the history of Psilocybin...
Journal of Psychiatry and Neuroscience
October 25, 2022
A. Reichelt
In an interesting and timely editorial, Borgland and Neyens provide a snap shot of preclinical research that could support the development of psyche delic drugs as part of a therapeutic regimen in individuals with obesity or eating disorders (EDs), including an orexia nervosa (AN) and binge eating disorder (BED).1 The role of the sero tonergic system in appetite was key in the development...